Accordingly, preliminary results of clinical studies of novel kinase inhibitor combinations containing CDKi suggest that presence of alterations in the Cyclin D-CDK4/6-p16INK4A-RB axis confers increased tumor cell responsiveness—which may lead to overall manageable safety profiles of these combinations and favorable efficacies [104]. The gene discussed is RB1; the disease is neoplasm.